Consider alternant therapies that are not reasonable CYP3A inducers all through procedure with mitapivat. If not able to keep away from coadministration, monitor Hb and titrate over and above fifty mg BID, if important, but usually do not exceed mitapivat dose of a hundred mg BID. . Keep track of